SBR Group OF Companies Pharmaceutical Import Profile — Liberia (DGFT 2022–2026)

Name: SBR Group OF Companies Pharmaceutical Import Records from India — 4 Products, $2.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

SBR Group OF Companies — Pharmaceutical Importer Profile (2026) | 4 Products, $2.6M Trade | TransData Nexus

SBR Group OF Companies

Pharmaceutical Importer · Liberia · Antibiotics Focus · $2.6M Total Trade · DGFT Verified

SBR Group OF Companies is a pharmaceutical importer based in Liberia with a total trade value of $2.6M across 4 products in 2 therapeutic categories. Based on 86 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. SBR Group OF Companies sources from 3 verified Indian suppliers, with Bhumi Pharmaceuticals accounting for 95.9% of imports.

SBR Group OF Companies — Import Portfolio & Supplier Network

SBR Group OF Companies import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to SBR Group OF Companies?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Bhumi Pharmaceuticals	$7.4M	2,254	95.9%
Bio Pharma Primo Impex	$265.5K	169	3.4%
Sydniee Biotech	$49.4K	5	0.6%

What Formulations Does SBR Group OF Companies Import?

Formulation	Value	Ships
Rl (compound sodium lactate intraveous	$219.2K	10
Betriaxone injection (combipack)	$121.2K	3
Metrokind 500 tablet (10x10	$115.7K	3
Ampistar 500 (10x10)(ampicillin	$114.3K	3
Ns(sodium chloride intraveous infision )	$113.5K	8
Malaria go 80/480 tablet (10x1x6	$111.3K	3
Bactmycin SUSP. 100ML (erythromycin BP	$110.3K	4
Night king 150 (10x1x5)(sildenafil	$110.0K	4
Cold clear kid syp (100 ML	$109.0K	3
React extra gel ( 30gmx12 )(diclofenac	$107.2K	4
Metrokind 250 tablet (10x10	$106.1K	3
Bunty s a.r.t 120MG INJ. (combipack	$104.0K	3
Asma (10x10)(salbutamol sulphate	$103.5K	3
Bunty s chloraphenicol eye drop( 10x	$103.0K	3
Gentastar ( 10x 10ML)( gentamicin	$102.7K	3

SBR Group OF Companies imports 1,574 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ampicillin	Antibiotics	$1.2M	24	0.8%	4
2	Erythromycin	Antibiotics	$800.0K	16	1.0%	7
3	Gentamicin	Antibiotics	$494.5K	24	1.0%	11
4	Mebendazole	Antimalarial & Antiparasitic	$138.1K	22	1.0%	16

SBR Group OF Companies imports 4 pharmaceutical products across 2 categories into Liberia totaling $2.6M.

SBR Group OF Companies — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

SBR Group of Companies is a prominent pharmaceutical importer and distributor based in Monrovia, Liberia. Operating primarily as a wholesaler, the company plays a pivotal role in ensuring the availability of essential medicines across the Liberian market. Their extensive import portfolio includes a diverse range of pharmaceutical formulations, catering to various therapeutic needs. The company's strategic sourcing from international suppliers, particularly from India, underscores its commitment to providing high-quality pharmaceutical products to the Liberian populace.

2Distribution Network

SBR Group of Companies maintains a centralized distribution hub in Monrovia, Liberia's capital, facilitating efficient logistics and timely delivery of pharmaceutical products nationwide. While specific warehouse locations and logistics capabilities are not detailed in the available data, the company's substantial import volume and diverse product range suggest a well-established infrastructure capable of supporting its distribution needs. The focus on sourcing from India indicates a streamlined supply chain, likely leveraging established shipping routes and partnerships to ensure consistent product availability.

3Industry Role

Within Liberia's pharmaceutical supply chain, SBR Group of Companies functions primarily as a wholesaler. By importing a wide array of finished pharmaceutical formulations, the company acts as a critical intermediary between international manufacturers and local healthcare providers. This role is essential in bridging the gap between global pharmaceutical production and the specific needs of the Liberian market, ensuring that healthcare facilities have access to necessary medications.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — SBR Group OF Companies

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

SBR Group of Companies exhibits a high degree of sourcing concentration, with 97.09% of its imports originating from India. This strategic choice likely aims to capitalize on India's robust pharmaceutical manufacturing capabilities and competitive pricing. The company's primary supplier, Bhumi Pharmaceuticals, accounts for 95.9% of the total import value, indicating a deep and stable relationship. While this concentration offers benefits such as streamlined logistics and potential cost savings, it also presents risks associated with over-reliance on a single supplier. Any disruptions in Bhumi Pharmaceuticals' operations could significantly impact SBR Group's supply chain.

2Supply Chain Resilience

The resilience of SBR Group of Companies' supply chain is closely tied to its dependence on Bhumi Pharmaceuticals. The lack of detailed information on backup suppliers and the diversity of formulations imported suggests limited diversification in sourcing strategies. This reliance could pose challenges in the event of supply chain disruptions, such as production delays or quality issues. Additionally, the absence of information regarding the regulatory compliance of key suppliers raises concerns about the consistency and quality of imported products.

Strategic Implications

Importing Pharmaceuticals into Liberia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Liberia

1Regulatory Authority & Framework

The Liberia Medicines and Health Products Regulatory Authority (LMHRA) is the statutory body responsible for regulating the importation, distribution, and use of medicines and health products in Liberia. Key legislation governing pharmaceutical imports includes the LMHRA Act of 2010, which outlines the requirements for import licenses and the registration of medicines. The marketing authorization pathway for Indian generics involves obtaining an importer's license from the LMHRA, ensuring that imported products meet the necessary safety, efficacy, and quality standards.

2Import Licensing & GMP

To import medicines and health products into Liberia, companies must obtain an importer's license from the LMHRA. This license is valid for one year and is issued upon confirmation that the importing facility complies with current Good Manufacturing Practice (GMP) guidelines as set by the World Health Organization (WHO). For Indian exporters, recognition of GMP certificates from the European Union (EU), WHO, or the Pharmaceutical Inspection Co-operation Scheme (PIC/S) is essential to meet LMHRA requirements. Additionally, wholesale distribution authorization is mandatory for entities involved in the distribution of pharmaceutical products within Liberia.

Quality & Labeling

SBR Group OF Companies — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

SBR Group of Companies' focus on importing antibiotics and antimalarial & antiparasitic medications aligns with Liberia's pressing healthcare needs. The dominance of antibiotics in their import portfolio reflects the high demand for treatments addressing bacterial infections prevalent in the region. The inclusion of antimalarial & antiparasitic drugs indicates a strategic response to the endemic nature of malaria and parasitic diseases in Liberia, highlighting the company's role in supporting public health initiatives.

2Sourcing Profile

SBR Group of Companies primarily sources generic drugs, emphasizing cost-effectiveness and accessibility. The company's preference for finished pharmaceutical formulations, as opposed to active pharmaceutical ingredients (APIs) or bulk drugs, suggests a focus on ready-to-use products that can be distributed efficiently within Liberia. India's well-established pharmaceutical manufacturing sector aligns with SBR Group's procurement strategy, offering a reliable supply of high-quality generics.

3Market Positioning

Based on its product mix, SBR Group of Companies serves a broad segment of the Liberian market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's extensive importation of essential medicines positions it as a key player in meeting the diverse pharmaceutical needs of the Liberian population, contributing to the overall healthcare infrastructure.

Seller's Guide — How to Become a Supplier to SBR Group OF Companies

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with SBR Group of Companies, particularly by offering a wider range of pharmaceutical products or more competitive pricing. Diversifying the supplier base could enhance SBR Group's resilience against potential supply chain disruptions and provide access to innovative formulations. Identifying gaps in SBR Group's current sourcing, such as unmet therapeutic needs or emerging market trends, could present avenues for collaboration and growth.

2Requirements & Qualifications

Indian exporters aiming to supply SBR Group of Companies and the Liberian market must possess certifications and quality standards recognized by the LMHRA. These include GMP certificates from the EU, WHO, or PIC/S, as well as wholesale distribution authorization. Compliance with LMHRA's import licensing requirements and adherence to quality control measures are essential to ensure successful market entry and sustained business relationships.

3How to Approach

Frequently Asked Questions — SBR Group OF Companies

What products does SBR Group OF Companies import from India?

SBR Group OF Companies imports 4 pharmaceutical products across 2 categories. Top imports: Ampicillin ($1.2M), Erythromycin ($800.0K), Gentamicin ($494.5K), Mebendazole ($138.1K).

Who supplies pharmaceuticals to SBR Group OF Companies from India?

SBR Group OF Companies sources from 3 verified Indian suppliers. The primary supplier is Bhumi Pharmaceuticals (95.9% of imports, $7.4M).

What is SBR Group OF Companies's total pharmaceutical import value?

SBR Group OF Companies's total pharmaceutical import value from India is $2.6M, based on 86 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does SBR Group OF Companies focus on?

SBR Group OF Companies imports across 2 categories. The largest: Antibiotics (94.8%), Antimalarial & Antiparasitic (5.2%).

Get Full SBR Group OF Companies Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.